2. Academic Validation
  3. PRMT6 functionally associates with PRMT5 to promote colorectal cancer progression through epigenetically repressing the expression of CDKN2B and CCNG1

PRMT6 functionally associates with PRMT5 to promote colorectal cancer progression through epigenetically repressing the expression of CDKN2B and CCNG1

  • Exp Cell Res. 2022 Nov 16;422(1):113413. doi: 10.1016/j.yexcr.2022.113413.
Yuzhong Chen 1,  Wanqing Liang 2,  Jun Du 3,  Jiachi Ma 3,  Rongrui Liang 4,  Min Tao 5
Affiliations

Affiliations

  • 1 Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China; Department of Surgical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, 233000, China.
  • 2 Bengbu Medical College, Bengbu, 233000, Anhui Province, China.
  • 3 Department of Surgical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, 233000, China.
  • 4 Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China; Department of Oncology, Dushu Lake Hospital Affiliated to Soochow University, Suzhou, 215124, China.
  • 5 Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China; Department of Oncology, Dushu Lake Hospital Affiliated to Soochow University, Suzhou, 215124, China. Electronic address: taomin@suda.edu.cn.
PMID: 36400182 DOI: 10.1016/j.yexcr.2022.113413
Abstract

Background: Protein arginine methyltransferase 6 (PRMT6) is a type I arginine methyltransferase that asymmetrically dimethylates histone H3 arginine 2 (H3R2me2a). However, the biological roles and underlying molecular mechanisms of PRMT6 in colorectal Cancer (CRC) remain unclear.

Methods: PRMT6 expression in CRC tissue was examined using immunohistochemistry. The effect of PRMT6 on CRC cells was investigated in vitro and in vivo. Mass spectrometry, co-immunoprecipitation and GST pulldown assays were performed to identify interaction partners of PRMT6. RNA-seq, chromatin immunoprecipitation, Western blot and qRT-PCR assays were used to investigate the mechanism of PRMT6 in gene regulation.

Results: PRMT6 is significantly upregulated in CRC tissues and facilitates cell proliferation of CRC cells in vitro and in vivo. Through RNA-seq analysis, CDKN2B (p15INK4b) and CCNG1 were identified as new transcriptional targets of PRMT6. PRMT6-dependent H3R2me2a mark was predominantly deposited at the promoters of CDKN2B and CCNG1 in CRC cells. Furthermore, PRMT5 was firstly characterized as an interaction partner of PRMT6. Notably, H3R2me2a coincides with PRMT5-mediated H4R3me2s and H3R8me2s marks at the promoters of CDKN2B and CCNG1 genes, thus leading to transcriptional repression of these genes.

Conclusions: PRMT6 functionally associates with PRMT5 to promote CRC progression through epigenetically repressing the expression of CDKN2B and CCNG1. These insights raise the possibility that combinational intervention of PRMT6 and PRMT5 may be a promising strategy for CRC therapy.

Keywords

CCNG1; CDKN2B; PRMT5; PRMT6; Proliferation.

Figures
Products